SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

21 marketing jobs

Revolution Medicines logo
6 months ago

Senior Director, Pipeline & Product Communications

Revolution Medicines

Redwood City, CA (On-site)Full time$244K/yr – $305K/yr
Previous
12
Next

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

21 jobs
Revolution Medicines logo

Senior Director, Pipeline & Product Communications

Revolution Medicines

Redwood City, CA (On-site)

$244K/yr - $305K/yrIn-houseFull-timeSenior level15+ years exp.
6 months ago
Previous12
Revolution Medicines logo
Revolution Medicines

Senior Director, Pipeline & Product Communications

Redwood City, CA (On-site)

$244K/yr – $305K/yrSenior Level15+ years expFull time

Posted 6 months ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Lead pipeline and product communications for a clinical-stage precision oncology company, aligning development milestones, launch readiness, and reputation management.

  • Own and manage the integrated pipeline and product communications strategy across development stages.
  • Must-have: 15+ years in biotech/pharma communications with pipeline/product experience in-house or at a top agency.
  • Standout: builds and leads high-performing teams, partnering with R&D, Medical Affairs, Regulatory, and Legal.

Job Description

Responsibilities

  • Own and lead the integrated pipeline and product communications strategy across all stages of development, ensuring clear differentiation, scientific credibility, and alignment with corporate and business priorities.
  • Direct communications for major clinical and regulatory milestones, including data readouts, congress presentations, trial initiations, filings, approvals, and pre-launch milestones, in close partnership with R&D, Medical Affairs, Regulatory, and Legal.
  • Serve as the senior communications advisor for launch readiness, shaping pre-launch and launch narratives across earned media, disease education, patient engagement, and stakeholder communications, with clear linkage to future commercial strategy.
  • Lead disease awareness and patient advocacy communications, ensuring responsible education, strong patient advocacy group partnerships, and integration of patient voice into pipeline and product storytelling.
  • Provide strategic counsel on value, access, and product-related issues, anticipating reputational risk and leading communications response to safety updates, competitive dynamics, and external scrutiny.
  • Drive scientific and medical thought leadership, positioning Revolution Medicines and its leaders as credible voices through publications, congress presence, executive visibility, and media engagement.
  • Build and lead a high-performing pipeline and product communications team, setting direction, developing talent, and ensuring consistent, high-quality execution.
  • Oversee agency partners and measurement frameworks, using insights to evaluate impact, optimize performance, and scale communications effectiveness.

Requirements

  • 15+ years of experience in biotech or pharmaceutical communications, including deep experience in pipeline and product communications in-house and/or at a leading agency.
  • Bachelor’s degree required in Communications or similar; advanced degree preferred
  • Demonstrated success supporting clinical development, regulatory milestones, and product launches, ideally in precision oncology or a similarly complex therapeutic area.
  • Proven people management experience, including leading teams and developing talent.
  • Strong leadership presence with the ability to influence senior stakeholders and lead cross-functional initiatives.
  • Deep understanding of the U.S. healthcare environment, including regulatory policy, R&D, pricing, and access.
  • Exceptional storytelling and writing skills, with the ability to translate complex science for diverse audiences.
  • Demonstrated experience managing sensitive issues and high-profile communications.
  • Track record of building relationships with top-tier scientific, medical, and industry media.

Preferred

  • Deep familiarity with precision oncology, including competitive landscapes, combination strategies, and evolving standards of care.
  • Proven success leading communications for major regulatory milestones, including FDA approvals, advisory committee meetings, and high-stakes data readouts.
  • Strong issues-management experience relating to global trial access and expanded access.
  • Track record of coordinating with corporate patient advocacy and patient advocacy organizations and integrating patient voice into pipeline and product storytelling.
  • History of leading large-scale disease education or awareness campaigns that shift understanding of disease complexity or heterogeneity.
  • Background spanning both product and corporate communications, enabling integrated decision-making across asset narratives and enterprise reputation.

Benefits

  • strong benefits
  • significant learning and development opportunities
Revolution Medicines logo

Revolution Medicines

3.5 Glassdoor

We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses.

Founded in 2014
Redwood City, California, USA
817 employees (26 in marketing)
www.revmed.com
54% recommend to a friend
64% CEO approval

Salaries

Posted range

$244K/yr – $305K/yr

Taken straight from the job posting.

See all Revolution Medicines salaries

Marketing Team

Marketing Team Size
26 (3% of company)
Median Career Experience
12 years
Median Tenure
1.5 years
Marketing Roles Posted (Last 30 Days)
2

People

Marketing Leadership

Wing Yeung
Wing Yeung
Director, Access Marketing
At the company for 1 year 3 months
Camellia Lock
Camellia Lock
Associate Director, Marketing
At the company for 1 year 7 months
Molly Klein-McDowell
Molly Klein-McDowell
Associate Marketing Director
At the company for 2 years
Kristen Eck
Kristen Eck
Senior Manager, Marketing Operations
At the company for 1 year 6 months

Funding

Total Funding
$2.3B
Last Raise
$250M
Post IPO Debt, 9 months ago

Funding History

  • Jun 2025
    Post IPO Debt • $250M
  • Dec 2024
    Post IPO Equity • $750M
  • Mar 2023
    Post IPO Equity • $323.6M

Traffic Signals

Monthly Visitors
50.4K
Traffic Source Mix
Search
39%
Direct
40.8%
Referral
7.9%
Social
11.8%
Paid
0.4%

Headcount Trend

Current headcount: ~817

Recent News

Revolution Medicines is 'within sight' of 1,000 employees and looking for a new office to fit them
Nov 17, 2025 • The Business Journals
Revolution Medicines (RVMD): Assessing Valuation After Recent 28% Monthly Share Price Surge
Nov 7, 2025 • Yahoo Finance
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
Nov 6, 2025 • Yahoo Finance
Does Revolution Medicines' Recent 27% Jump Reflect Its Real Value?
Nov 6, 2025 • simplywall.st
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
Nov 5, 2025 • GlobeNewswire
Revolution Medicines Inc (RVMD) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...
Nov 5, 2025 • Yahoo Finance
Revolution Medicines to Participate in November 2025 Investor Conferences
Nov 4, 2025 • GlobeNewswire
Revolution Medicines Inc (RVMD) Q3 2025: Everything You Need To Know Ahead Of Earnings
Nov 4, 2025 • Yahoo Finance
Revolution Medicines a new outperform at RBC on RAS(ON) inhibitors for cancers
Nov 3, 2025 • Seeking Alpha
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor
Oct 27, 2025 • GlobeNewswire
Revolution Medicines stock rises after FDA grants Orphan Drug Designation
Oct 27, 2025 • Investing.com
Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
Oct 24, 2025 • The Cancer Letter
Triple meeting 2025 – Revolution hints at post-KRAS promise | ApexOnco - Clinical Trials news and analysis
Oct 23, 2025 • Oncology Pipeline
Revolution Medicines Snags One of First New FDA Vouchers to Speed Review
Oct 22, 2025 • Inside Precision Medicine
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
Oct 22, 2025 • Yahoo Finance
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
Oct 22, 2025 • GlobeNewswire
Mizuho initiates Revolution Medicines stock with Outperform rating
Oct 20, 2025 • Investing.com
Revolution Medicines: A Big Deal, But With A Big Price Tag (NASDAQ:RVMD)
Oct 20, 2025 • Seeking Alpha
Revolution Medicines (RVMD): Examining Valuation After Recent Stock Momentum and Long-Term Gains
Oct 20, 2025 • Yahoo Finance
Jim Cramer Says Revolution Medicines “Is a Speculative Situation”
Oct 19, 2025 • Yahoo Finance
Revolution Medicines Receives FDA Voucher for Daraxonrasib Under National Priority Voucher Pilot Program
Oct 17, 2025 • Quiver Quantitative
Revolution Medicines stock surges after FDA grants priority voucher
Oct 17, 2025 • Investing.com
Revolution Medicines Awarded Voucher for Daraxonrasib
Oct 17, 2025 • GlobeNewswire
Revolution Medicines Stock Gains Momentum: Here’s Why
Oct 8, 2025 • TipRanks
Revolution Medicines’ SWOT analysis: RAS inhibitor stock poised for growth amid fierce competition
Oct 8, 2025 • Investing.com
Did Leadership Moves Just Shift Revolution Medicines' (RVMD) Investment Narrative Ahead of Key Launches?
Oct 7, 2025 • Yahoo Finance
Assessing Revolution Medicines After Recent Cancer Breakthrough and 15% Monthly Rally
Oct 6, 2025 • Yahoo Finance
Revolution Medicines, Inc. (RVMD) Insider Sells Shares
Oct 2, 2025 • Yahoo Finance
Revolution Medicines Shows Improved Relative Strength; Still Shy Of Benchmark
Sep 30, 2025 • Investor's Business Daily
Revolution Medicines appoints new chief development officer
Sep 29, 2025 • Investing.com
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
Sep 29, 2025 • Yahoo Finance
Former Mirati and Genentech Executive Alan Sandler Joins Revolution Medicines to Lead RAS Cancer Programs
Sep 29, 2025 • Stock Titan
Revolution Medicines Stock Soars Amid Strategic Moves
Sep 29, 2025 • TipRanks
Revolution Medicines appoints Alan Sandler as CDO
Sep 29, 2025 • thefly.com
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
Sep 29, 2025 • Revolution Medicines, Inc.
Cislini Jeff, general counsel at Revolution Medicines, sells $79,623 in stock
Sep 26, 2025 • Investing.com
Revolution Medicines price target raised by $1 at JPMorgan, here's why
Sep 25, 2025 • thefly.com
Revolution Medicines Insider Sold Shares Worth $614,558, According to a Recent SEC Filing
Sep 18, 2025 • MarketScreener
Revolution Medicines Insider Sold Shares Worth $5,557,754, According to a Recent SEC Filing
Sep 16, 2025 • MarketScreener
The week in pharma: action, reaction and insight – week to September 12
Sep 14, 2025 • Pharma Letter
REVOLUTION Medicines
Sep 12, 2025 • Pharma Letter
Revolution advances daraxonrasib to Phase III in pancreatic cancer
Sep 12, 2025 • Pharma Letter
Revolution Medicines: Shares Soar On Pancreatic Cancer Study Win - I'm Sold (NASDAQ:RVMD)
Sep 11, 2025 • Seeking Alpha
Revolution’s daraxonrasib moves to Phase III after PDAC hat-trick
Sep 11, 2025 • Clinical Trials Arena
Revolution Medicines’ Surging Potential: What’s Happening?
Sep 11, 2025 • StocksToTrade
Revolution Medicines (RVMD) Announces Promising Phase 1 Daraxonrasib Clinical Trial Results
Sep 11, 2025 • Yahoo Finance
Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug
Sep 11, 2025 • Benzinga.com
Revolution takes early stage cues for a phase III in pancreatic cancer
Sep 11, 2025 • BioWorld Financial Watch
Revolution Medicines rises 14.2%
Sep 11, 2025 • thefly.com
Transcript : Revolution Medicines, Inc. - Special Call
Sep 11, 2025 • MarketScreener
Revolution Medicines announces results from daraxonrasib Phase 1 trials
Sep 11, 2025 • thefly.com
Revolution Medicines rises on daraxonrasib data that supports phase 3 program
Sep 10, 2025 • Seeking Alpha
Revolution Medicines Reports Promising Phase 1 Study Results
Sep 10, 2025 • TipRanks
Revolution Medicines Reports Promising Long-term Data for Daraxonrasib in Metastatic Pancreatic Cancer and Announces Phase 3 Trial Plans
Sep 10, 2025 • Quiver Quantitative
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
Sep 10, 2025 • GlobeNewswire
Revolution Medicines (RVMD): Assessing Valuation After Truist Highlights Potential of RAS-mutant Cancer Pipeline
Sep 9, 2025 • Yahoo Finance
Revolution Medicines (RVMD) Is Up 6.7% After Truist’s Bullish Initiation Is the Pipeline Rethink Underway?
Sep 8, 2025 • Yahoo Finance
Revolution Medicines stock initiated with Buy rating at Truist Securities
Sep 5, 2025 • Investing.com
Oppenheimer Reaffirms Outperform on Revolution Medicines (RVMD) Amid RAS Therapy Progress
Sep 1, 2025 • Yahoo Finance
Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines
Aug 29, 2025 • Yahoo Finance
This Parker-Hannifin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Aug 15, 2025 • Benzinga.com
Revolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib for Lung Cancer
Aug 13, 2025 • Yahoo Finance
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
Aug 12, 2025 • BioSpace
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
Aug 11, 2025 • MarketScreener
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
Aug 11, 2025 • Business Wire
Revolution Medicines August 2025 slides: advancing RAS inhibitor pipeline with promising data
Aug 7, 2025 • Investing.com
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
Aug 6, 2025 • Yahoo Finance
Royalty Pharma Reports Second Quarter 2025 Results
Aug 6, 2025 • Royalty Pharma plc
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
Aug 6, 2025 • Revolution Medicines, Inc.
Revolution Medicines Q2 Loss Widens
Aug 6, 2025 • MarketScreener
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
Jul 30, 2025 • GlobeNewswire
Iambic Therapeutics and Revolution Medicines Announce AI-Driven Oncology Collaboration
Jul 30, 2025 • globallegalchronicle.com
Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade
Jul 28, 2025 • Nasdaq
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
Jul 24, 2025 • GlobeNewswire
iOnctura Appoints Dr. Neil Gallagher and Anthony Mancini To Board
Jul 24, 2025 • citybiz
iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments
Jul 24, 2025 • PR Newswire UK
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
Jul 23, 2025 • Yahoo Finance
Revolution Medicines announces FDA BTD to elironrasib
Jul 23, 2025 • thefly.com
Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs
Jul 16, 2025 • Yahoo Finance
Revolution Medicines Fair Value call captures 40% downside in biotech stock
Jul 14, 2025 • Investing.com
Wilson Sonsini Advises Iambic Therapeutics on Technology and Research Collaboration with Revolution Medicines
Jul 10, 2025 • Wilson Sonsini
Revolution lines up Iambic's AI platform in discovery collab worth up to $25M
Jul 9, 2025 • Fierce Biotech
Iambic and Revolution Medicines Partner on AI Cancer Drug Discovery
Jul 9, 2025 • Genetic Engineering and Biotechnology News
Revolution Medicines and Iambic Announce Technology and
Jul 9, 2025 • GlobeNewswire
Revolution Medicines’ Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations
Jul 8, 2025 • Yahoo Finance
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors
Jul 6, 2025 • Yahoo Finance
Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress
Jul 2, 2025 • Yahoo Finance
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
Jun 30, 2025 • GlobeNewswire
Revolution Medicines, Summit Therapeutics Enter Clinical Collaboration
Jun 30, 2025 • Nasdaq
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
Jun 30, 2025 • Business Wire
Revolution Medicines partners Royalty Pharma on $2bn funding
Jun 25, 2025 • Pharmaceutical Technology
Latham & Watkins Advises Revolution Medicines on US$2 Billion Growth Financing With Royalty Pharma
Jun 24, 2025 • Latham & Watkins LLP
Revolution Medicines secures $2 billion funding deal with Royalty Pharma
Jun 24, 2025 • Investing.com
Revolution Medicines Secures $2 Billion Funding Agreement
Jun 24, 2025 • TipRanks
Revolution's RAS-driven ambitions get $2B boost from Royalty Pharma
Jun 24, 2025 • FirstWord Pharma
Revolution Establishes Endless Cash Runway With $2B Royalty Pharma Deal
Jun 24, 2025 • BioSpace
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
Jun 24, 2025 • GlobeNewswire
Royalty signs off on $2B to bankroll Revolution's RAS cancer drug's road to regulators
Jun 24, 2025 • Fierce Biotech
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
Jun 24, 2025 • Reuters
Revolution Medicines Partners Royalty Pharma On $2 Bln Flexible Funding
Jun 24, 2025 • Nasdaq

Links

www.revmed.comLinkedInCrunchbase